This evident role in cell death resistance may explain why PON2 levels in pediatric acute lymphatic leukemia (ALL) and chronic myeloic leukemia (CML) were associated with poor prognosis and resistance against Imatinib, respectively [27], [28], [29]. The gene discussed is PON2; the disease is acute lymphoblastic leukemia.